Is Roku Stock Undervalued Now?
At roughly $89 a share, Roku (NASDAQ: ROKU) trades for barely…
Sell
34
PTCT Quote, Financials, Valuation and Earnings
Last price:
$48.59
Seasonality move
:
9.1%
Day range:
$48.05 - $49.42
52-week range:
$29.02 - $58.38
Dividend yield:
0%
P/E ratio:
7.46x
P/S ratio:
2.17x
P/B ratio:
--
Volume:
760.8K
Avg. volume:
1.1M
1-year change:
46.23%
Market cap:
$3.8B
Revenue:
$806.8M
EPS (TTM):
$6.51
Analysts' Opinion
-
Consensus RatingPTC Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $62.81, PTC Therapeutics has an estimated upside of 29.38% from its current price of $48.55.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $40.00 representing 17.61% downside risk from its current price of $48.55.
Fair Value
-
According to the consensus of 13 analysts, PTC Therapeutics has 29.38% upside to fair value with a price target of $62.81 per share.
PTCT vs. S&P 500
-
Over the past 5 trading days, PTC Therapeutics has underperformed the S&P 500 by -0.75% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
PTC Therapeutics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
PTC Therapeutics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter PTC Therapeutics reported revenues of $1.2B.
Earnings Growth
-
PTC Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter PTC Therapeutics reported earnings per share of $10.04.
Enterprise value:
2.1B
EV / Invested capital:
--
Price / LTM sales:
2.17x
EV / EBIT:
2.60x
EV / Revenue:
1.19x
PEG ratio (5yr expected):
--
EV / Free cash flow:
3.10x
Price / Operating cash flow:
5.67x
Enterprise value / EBITDA:
2.51x
Gross Profit (TTM):
$1.7B
Return On Assets:
30.02%
Net Income Margin (TTM):
33.56%
Return On Equity:
--
Return On Invested Capital:
-382.54%
Operating Margin:
82.43%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $770.4M | $927.6M | $1.8B | $210.1M | $1.2B | |
| Gross Profit | $721.8M | $861.5M | $1.7B | $195.4M | $1.2B | |
| Operating Income | -$456.9M | -$279.7M | $868.3M | -$45.6M | $969.5M | |
| EBITDA | -$360.6M | -$254M | $839.1M | $11.5M | $971.1M | |
| Diluted EPS | -$7.89 | -$7.68 | $6.51 | -$1.20 | $10.04 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $1.1B | $774M | $613.4M | $1.2B | $2.3B | |
| Total Assets | $2.1B | $1.8B | $1.6B | $1.8B | $2.7B | |
| Current Liabilities | $250.9M | $476.8M | $441.6M | $574.5M | $595.4M | |
| Total Liabilities | $1.8B | $1.9B | $2.1B | $2.7B | $2.8B | |
| Total Equity | $292.6M | -$90.6M | -$457.6M | -$893.9M | -$185.8M | |
| Total Debt | $430M | $431.9M | $572.1M | $284.5M | $285.7M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$288.7M | -$58.2M | $691.7M | $70.8M | $870.1M | |
| Cash From Investing | $212.2M | -$262.7M | -$25.2M | -$114.9M | -$184.4M | |
| Cash From Financing | $170.9M | $642.8M | $264.7M | $540K | $9.4M | |
| Free Cash Flow | -$403.4M | -$199.5M | $679.2M | $6.4M | $867.6M | |
PTCT
Sector
Market Cap
$3.8B
$33.5M
Price % of 52-Week High
83.16%
48.01%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.97%
1-Year Price Total Return
46.24%
-33.61%
Beta (5-Year)
0.501
0.621
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$48.66
200-day SMA
Buy
Level
$46.28
Bollinger Bands (100)
Sell
Level
45.31 - 53.29
Chaikin Money Flow
Buy
Level
401.5K
20-day SMA
Sell
Level
$49.56
Relative Strength Index (RSI14)
Sell
Level
46.94
ADX Line
Buy
Level
17.27
Williams %R
Neutral
Level
-63.7224
50-day SMA
Buy
Level
$48.17
MACD (12, 26)
Buy
Level
10.84
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
361.4K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.5979)
Sell
CA Score
(Annual)
Level (-5.5202)
Buy
Beneish M-Score
(Annual)
Level (-3.3947)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (7.7623)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (8)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.
Stock Forecast FAQ
In the current month, PTCT has received 8 Buy ratings 5 Hold ratings, and 0 Sell ratings. The PTCT average analyst price target in the past 3 months is $62.81.
-
Where Will PTC Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that PTC Therapeutics share price will rise to $62.81 per share over the next 12 months.
-
What Do Analysts Say About PTC Therapeutics?
Analysts are divided on their view about PTC Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that PTC Therapeutics is a Sell and believe this share price will drop from its current level to $40.00.
-
What Is PTC Therapeutics's Price Target?
The price target for PTC Therapeutics over the next 1-year time period is forecast to be $62.81 according to 13 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is PTCT A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for PTC Therapeutics is a Buy. 8 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of PTCT?
You can purchase shares of PTC Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase PTC Therapeutics shares.
-
What Is The PTC Therapeutics Share Price Today?
PTC Therapeutics was last trading at $48.59 per share. This represents the most recent stock quote for PTC Therapeutics. Yesterday, PTC Therapeutics closed at $48.55 per share.
-
How To Buy PTC Therapeutics Stock Online?
In order to purchase PTC Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Microsoft Be a $5 Trillion Stock?
Microsoft’s market capitalization sits near $3.73 trillion today. To clear the…
Where Will C3.ai Stock Be in 1 Year?
C3 .ai (NYSE: AI) has been the poster child for “hype versus execution.”…
Stock Ideas
Buy
69
Is NVDA Stock a Buy?
Market Cap: $4T
P/E Ratio: 56x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 43x
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
58
INKT alert for Jul 12
MiNK Therapeutics [INKT] is up 727.94% over the past day.
Buy
51
NEGG alert for Jul 12
Newegg Commerce [NEGG] is up 74.03% over the past day.
Buy
68
ATRO alert for Jul 12
Astronics [ATRO] is up 16.28% over the past day.
